CIPLA About the founder of CIPLA Abdul Hamied

Khwaja Abdul Hamied, the founder of Cipla, was born on October 31, 1898. The fire of nationalism was kindled in him when he was 15 as he witnessed a wanton act of colonial highhandedness. The fire was to blaze within him right through his life. In college, he found Chemistry fascinating. He set sail for Europe in 1924 and got admission in Berlin University as a research student of "The Technology of Barium Compounds". He earned his doctorate three years later. In October 1927, during the long voyage from Europe to India, he drew up great plans for the future. He wrote: "No modern industry could have been possible without the help of such centres of research work where men are engaged in compelling nature to yield her secrets to the ruthless search of an investigating chemist." His plan found many supporters but no financiers. However, Dr Hamied was determined to being "a small wheel, no matter how small, than be a cog in a big wheel."

Cipla Initiates Asthma Alert Schools campaign in Kolkata In an initiative to empower teachers and school authorities to handle asthma emergencies in schools, 'Breathe free', a public service initiative by Cipla launched a campaign called Asthma Alert Schools in Kolkata recently. It is the first ever initiative in India through which teachers would be trained to administer first-aid medication during an asthma attack and guided to identify symptoms of asthma in a child and to effectively communicate it to the parent. The campaign was initiated today with 200 teachers from over 40 schools of Kolkata who participated in the first workshop of Asthma Alert Schools and would reach out to many more schools in the coming months. 15 Oct 2010 Cipla looks to acquire 25% stake in South African co Drug major Cipla said it could take a decision to buy stake of up to 25 per cent in a unit of South Africa-based, Cipla Medpro in its next board meeting in October. Cipla Medpro is a partner of the Indian firm and is the third biggest drug maker in South Africa but Cipla does not hold any stake in the company. The Indian firm exports around 35 per cent of its production, mainly HIV-AIDS drugs, to the African continent and around 15 per cent of its export revenues are through Cipla Medpro. 3 Sep 2010 Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today the expansion of its generic product development alliance with Cipla Ltd., the second largest pharmaceutical company in India. The companies' original agreement was announced in December 2002.

Under the terms of the expanded agreement, the companies will work together to develop the additional products. Watson will be responsible for pursuing regulatory approvals for all developed products. Cipla will manufacture the products and Watson will have exclusive United States marketing rights.